A recent clinical case has identified an unprecedented dual malignancy in the mandible, where multiple myeloma (MM) and ...
Modifiable risk factors such as alcohol consumption, BMI, dietary patterns and smoking could shift cancer risk as much as 60% ...
TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts ...
MedPage Today on MSN
Decnupaz Approved for Rare Blood Cancer
Complete remission rate of 69% in blastic plasmacytoid dendritic cell neoplasm ...
As AbbVie continues to capitalize on its ImmunoGen deal, the growth of commercial antibody-drug conjugate (ADC) Elahere, another of the acquired company’s clinical assets has crossed the FDA finish ...
Cellectis doses first patient with BPDCN in phase I study of UCART123: New York Saturday, August 19, 2017, 18:00 Hrs [IST] Cellectis, a clinical-stage biopharmaceutical company fo ...
Fast track status supports expedited development/review for a serious hematologic malignancy with limited second-line therapy after HMA failure. CyTAC engineering merges small-molecule CCR2 binding ...
A Bhiwandi doctor, accused of fabricating a breast cancer diagnosis using a fake hospital letterhead, has been acquitted ...
The CD123-directed antibody and alkylating agent conjugate led to complete remission or clinical complete remission in nearly ...
We've come to accept that the gradual corruption of successful companies is as natural and inevitable as gravity,” writes ...
If you or a loved one was diagnosed with cutaneous T-cell lymphoma (CTCL) while taking Dupixent, you may be wondering whether ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results